Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.

Hao Xie,Mitesh J. Borad,Daniel H. Ahn,Tanios Bekaii-Saab,Nguyen H. Tran,Zhaohui Jin,Henry C. Pitot,Lucas J. Huebner,Qian Shi,Jaclynn Wessling,Lori Durgin,Minetta C. Liu,Tara L. Hogenson,William J. Phillips,Martin E. Fernandez–Zapico,Steven R. Alberts,Amit Mahipal

Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.

2020

Hao Xie
Mitesh J. Borad
Daniel H. Ahn
Tanios Bekaii-Saab
Nguyen H. Tran
Zhaohui Jin
Henry C. Pitot
Lucas J. Huebner
Qian Shi
Jaclynn Wessling
Lori Durgin
Minetta C. Liu
Tara L. Hogenson
William J. Phillips
Martin E. Fernandez–Zapico
Steven R. Alberts
Amit Mahipal

TPS594Background: Effective treatment options are very limited for patients with advanced refractory biliary tract cancer (BTC). Fluoropyrimidine-based chemotherapy regimen such as 5-fluorouracil a...

Keywords:

Irinotecan
Gastroenterology
Cancer
Biliary tract
Internal medicine
Medicine
Pathology
Refractory
biliary tract cancer
Chemotherapy regimen
effective treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations